# Decrescendo (NCT04675827)

> De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04675827
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: Jules Bordet Institute
- Conditions: HER2-positive Breast Cancer; ER-Negative Breast Cancer; PR-Negative Breast Cancer; Node-negative Breast Cancer
- Interventions: Pertuzumab and tratuzumab fixed dose combination; Trastuzumab emtansine
- Enrollment: 139
- Primary outcome: 3-year RFS in HER2-enriched subjects who achieve a pCR

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 7
- X threads: 6
- Podcasts: 4
- Bluesky threads: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=decrescendo-nct04675827

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04675827", "email": "<work email>"}; the inbox owner confirms by the emailed link.